Clinical features and treatment of childhood malignant lymphoma in Uganda
β Scribed by J. L. Ziegler; R. H. Morrow Jr.; A. C. Templeton; C. Templeton; A. Z. Bluming; L. Fass; S. K. Kyalwazi
- Publisher
- John Wiley and Sons
- Year
- 1970
- Tongue
- French
- Weight
- 915 KB
- Volume
- 5
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
A series of 66 patients with Burkitt's lymphoma or childhood lymphoma of the histiocytic or lymphoblastic type has been analysed. The six patients with histiocytic lymphomas had clinical features, response to therapy and survival rates which clearly distinguished this group from Burkitt's lymphoma. Of the six patients with lymphoblastic lymphomas, however, three presented with clinical features indistinguishable from Burkitt's lymphoma while two had facial tumors which showed atypical features. The response to chemotherapy with CTX was more favorable in the lymphoblastic than in the histiocytic group, and the survival rate in this small number of patients falls midway between those of histiocytic lymphoma and Burkitt's lymphoma. Thus, the clinical evaluation of Ugandan children with lymphoblastic lymphoma did not clearly distinguish this group from patients with Burkitt's lymphoma, and casts some doubt on the use of clinical features or response to therapy as diagnostic criteria.
π SIMILAR VOLUMES
## Abstract ## Background Sex hormone deficiency, growth hormone deficiency, skeletal irradiation, and treatment with corticosteroids or methotrexate may all cause reduction in bone mass after treatment for childhood malignant lymphoma. Previous studies of the bone mass of childhood cancer survivo
## Abstract ## Background Sex hormone deficiency or growth hormone deficiency may cause excess fatness after treatment for childhood malignant lymphoma. Previous studies of the body composition after treatment for childhood cancer included few survivors of malignant lymphoma who were not analysed
## Abstract Thirtyβthree patients with primary gastrointestinal lymphoma (GIL) followed at Ankara University Medical School have been evaluated. The most frequent locations of the disease are the small intestine (48.4%) and the stomach (39.3%). The intermediate and high grade lymphomas constitute 8